Vodori has launched what it calls the Regulated Content Intelligence Platform (RCIP), describing it as a new enterprise software category for life sciences. The platform combines a system of record for governed knowledge with AI-powered assistance for authoring, reviewing, approving, and distributing regulated content. RCIP embeds AI within the regulated content lifecycle, applying approved claims, scientific evidence, references, and compliance policies throughout the process. The first capability, Content Preflight, identifies spelling, grammar, formatting, and branding issues before formal Medical, Legal, and Regulatory review begins. According to Vodori's 2025 benchmarks report, nearly half of promotional content recirculation stems from preventable issues. The platform aims to reduce unnecessary review cycles whilst allowing reviewers to focus on scientific accuracy and regulatory decisions. Vodori plans to roll out additional capabilities through 2027, including Claims Intelligence in October and Regulatory Intelligence in early 2027. The company launched an Innovation Partner Programme in Q2 to help validate the platform architecture.

Vodori and BridgeView announce strategic partnership to transform content review across the life science industry. Turnkey MLR solution enables 30-60% faster review cycles with compliance and scalability built in CHICAGO, IL, UNITED STATES, January 8, 2026 /EINPresswire.com/ - Vodori, the leading provider of cloud-based compliant content management solutions for life sciences, and Bridgeview, a full-service consulting partner and a Zensar company, today announced a new partnership focused on helping life sciences companies modernize and streamline their promotional and medical content review process. The partnership combines Vodori's proven Medical-Legal-Regulatory Content Review (MLR) technology with BridgeView's regulatory expertise and implementation support to offer complete, compliant, and scalable solutions for teams across pharma, biotech, and medtech. Whether preparing for launch, expanding into new markets, or replacing legacy systems, life sciences companies can now simplify their MLR operations and accelerate time-to-approval. Together, Vodori and Bridgeview deliver a solution that includes: - A validated, compliance-ready MLR platform: Vodori's platform provides 21 CFR Part 11 and EU Annex 11 compliance, audit-ready workflows, real-time cross-functional collaboration, and modern digital content review. Customers reduce review cycles by 30 - 60%, enabling faster market execution. - Expert-led implementation, SOP guidance, and change management: Bridgeview complements the technology with hands-on configuration and implementation services, SOP development, training, content migration, and change management support tailored to the unique needs of life science teams. "Life sciences companies of all sizes deserve the same level of compliance confidence and delivery speed," said Scott Rovegno, Founder and CEO at Vodori. "Our partnership with BrideView brings together scalable technology and deep domain expertise to help customers modernize how they manage content and do it without complexity or delays." Mihales Karasavas, CCO, BridgeView Life Sciences, added, "Every day counts toward a patient receiving a life-changing therapy and BridgeView is dedicated to bringing world-class digital transformation to the life sciences sector. By pairing Vodori's MLR technology with our deep operational expertise, we are giving our clients a scalable, end-to-end framework to launch faster while ensuring compliance foundational to their success." Both Vodori and BridgeView have been recognized by Salesforce as Life Science Cloud partners, reinforcing their leadership in delivering modern, integrated solutions across the ecosystem. Life sciences organizations interested in accelerating compliant content review and simplifying MLR operations can learn more at vodori.com. About Vodori Vodori delivers cloud-based software that helps life sciences companies bring compliant content to market faster. We help commercial, clinical, regulatory, and quality functions streamline the review, approval, and distribution of promotional, scientific, and medical content. Vodori supports emerging, SMB, and enterprise customers across the globe and is Salesforce's exclusive MLR partner for Life Sciences Cloud. Follow Vodori via: Vodori Blog: https://www.vodori.com/blog LinkedIn: https://www.linkedin.com/company/vodori Website: www.vodori.com About Zensar At Zensar, we are 'experience-led everything.' We conceptualize, design, engineer, market, and manage digital solutions and experiences for 145+ leading enterprises. Using our 3Es of experience, engineering, and engagement, we harness the power of technology, creativity, and insight to deliver impact. Part of the $4.8 billion RPG Group, we are headquartered in Pune, India. Our 10,000+ employees work across 30+ locations worldwide, including Milpitas, Seattle, Princeton, Zurich, Cape Town, London, Singapore, and Mexico City. Follow Zensar via: Zensar Blog: http://www.zensar.com/blogs Twitter: https://twitter.com/Zensar LinkedIn: https://www.linkedin.com/company/zensar-technologies Facebook: https://www.facebook.com/ZensarTech/ Website: www.zensar.com Annalise Ludtke Vodori +1 269-808-0012 [email protected] EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]

Tact.ai, a Sunnyvale, Calif.-based provider of customer engagement software to life science organizations, added $33 million in a new round of funding from dRx Capital, M12, Salesforce Ventures, Eli Lilly & Co. and McKesson Ventures.